5-三氟甲基-2-氧化吲哚 | 71293-62-4

• 物质功能分类: 医药中间体 - 吲哚类化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 中文名称: 5-三氟甲基-2-氧化吲哚
• 中文别名: 5-三氟甲基氧化吲哚；5-三氟甲基吲哚啉-2-酮；5-三氟甲基吲哚-2-酮；5-(三氟甲基)氧化吲哚
• 英文名称: 5-trifluoromethyl-2-oxindole
• 英文别名: 5-trifluoromethyl-2-indolinone；5-(Trifluoromethyl)indolin-2-one；5-(trifluoromethyl)-1,3-dihydroindol-2-one
• CAS: 71293-62-4
• 化学式: C₉H₆F₃NO
• 分子量: 201.148
• InChiKey: RANTVMNWZIWPNR-UHFFFAOYSA-N

物化性质

• 熔点：
  182-186
• 沸点：
  283.4±40.0 °C(Predicted)
• 密度：
  1.391±0.06 g/cm3(Predicted)
• 溶解度：
  可溶于氯仿、DMSO、甲醇（微溶）

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  14
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  29.1
• 氢给体数：
  1
• 氢受体数：
  4

安全信息

• 危险品标志：
  Xi
• 海关编码：
  2933790090
• WGK Germany：
  3

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 5-Trifluoromethyloxindole
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 5-Trifluoromethyloxindole
CAS number: 71293-62-4

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C9H6F3NO
Molecular weight: 201.1

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, hydrogen fluoride.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  5-三氟甲基-2-氧化吲哚 以65%的产率得到
  参考文献：
  名称：

  Rewcastle Gordon W., Palmer Brian D., Dobrusin Ellen M., Fry David W., Kr+, J. Med. Chem, 37 (1994) N 13, S 2033-2042

  摘要：

  DOI：
• 作为产物：
  描述：

  3-Methylthio-5-trifluormethyloxindol 在 锌 溶剂黄146 、 氨 作用下， 以 溶剂黄146 为溶剂， 反应 1.0h， 以to give 5-trifluoromethyloxindole [VII: R1 =5-CF3, R3 =H] (7.22 g, 90%)的产率得到5-三氟甲基-2-氧化吲哚
  参考文献：
  名称：

  2-thioindoles (selenoindoles) and related disulfides (selenides) which

  摘要：

  本发明公开了2-硫代吲哚（2-硒代吲哚）及类似的2-吲哚硫酮（2-吲哚硒酮）和多硫化物（硒化物）化合物，其盐，生产方法，生产中间体，含有该化合物的药物组成物以及使用该组成物抑制哺乳动物中蛋白激酶依赖性疾病或治疗异常细胞生长的方法。

  公开号：

  US05556874A1

文献信息

• Synthesis of 3-[4-(dimethylamino)phenyl]alkyl-2-oxindole derivatives and their effects on neuronal cell death
  作者：Kyoji Furuta、Yu Kawai、Yosuke Mizuno、Yurika Hattori、Hiroko Koyama、Yoko Hirata

  DOI：10.1016/j.bmcl.2017.08.005

  日期：2017.9

  oxindole skeleton by anion-based methods provided additional substituted derivatives for structure-activity relationship studies. Their effects on neuronal cell death induced by oxidative stress were evaluated by lactate dehydrogenase assay. Compounds with the alkyl chain length of 2–4 significantly suppressed the neuronal cell death. No significant change occurred in the activity by substitution with

  通过以下两种途径之一合成了新型3- [4-（二甲基氨基）苯基]烷基-2-氧吲哚类似物：（1）羟吲哚与（4-二甲基氨基）肉桂醛加氢的Knoevenagel缩合序列，或（2 ）用[（4-二甲基氨基）苯基]烷基卤化物对羟吲哚二价阴离子进行烷基化。随后通过基于阴离子的方法在羟吲哚骨架的C-3和/或N-1处进行烷基化，为结构-活性关系研究提供了额外的取代衍生物。通过乳酸脱氢酶测定评估它们对氧化应激诱导的神经元细胞死亡的影响。烷基链长为2-4的化合物可显着抑制神经元细胞死亡。通过用极性较小的基团取代，活性没有发生显着变化。
• [EN] KINASE INHIBITORS AND METHOD OF TREATING CANCER WITH SAME<br/>[FR] INHIBITEURS DE KINASES ET PROCÉDÉ DE TRAITEMENT DU CANCER AVEC CEUX-CI
  申请人：UNIV HEALTH NETWORK

  公开号：WO2010115279A1

  公开（公告）日：2010-10-14

  The invention is directed to a compound represented by the following structural formula and pharmaceutically acceptable salts thereof: Compounds represented by this structural formula are kinase inhibitors and are therefore disclosed herein for the treatment of cancer. Definitions for the variables in the structural formula are provided herein.

  这项发明涉及一种由以下结构式表示的化合物及其药用可接受的盐：由该结构式表示的化合物是激酶抑制剂，因此在此披露用于治疗癌症。结构式中变量的定义在此提供。
• HETEROCYCLICALLY SUBSTITUTED METHOXYPHENYL DERIVATIVES WITH AN OXO GROUP, PROCESSES FOR PREPARATION THEREOF AND USE THEREOF AS MEDICAMENTS
  申请人：KEIL Stefanie

  公开号：US20120004165A1

  公开（公告）日：2012-01-05

  Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments The invention relates to heterocyclically substituted methoxyphenyl derivatives with an oxo group, and to physiologically compatible salts thereof. The invention relates to compounds of the formula I in which R1, R2, R3, R4, R10, X, n, B 1 , B 2 , B 3 and B 4 are each defined as specified, and to the physiologically compatible salts thereof. The compounds are suitable, for example, for treatment of diabetes.

  含有氧代基的杂环取代甲氧基苯基衍生物，其制备方法及用途作为药物。该发明涉及含有氧代基的杂环取代甲氧基苯基衍生物，以及其生理兼容盐。该发明涉及以下式I的化合物 其中R1、R2、R3、R4、R10、X、n、B1、B2、B3和B4分别如规定所定义，以及其生理兼容盐。这些化合物适用于例如糖尿病的治疗。
• [EN] NEW COMPOUNDS<br/>[FR] NOUVEAUX COMPOSES
  申请人：ASTRAZENECA AB

  公开号：WO2003082853A1

  公开（公告）日：2003-10-09

  The present invention provides new compounds of formula Ia and Ib: as well as a process for their preparation and new intermediates used therein, pharmaceutical formulations containing said therapeutically active compounds and to the use of said active compounds in therapy.

  本发明提供了式Ia和Ib的新化合物，以及它们的制备方法和在其中使用的新中间体，含有这些治疗活性化合物的药物配方，以及这些活性化合合物在治疗中的使用。
• Substituted pyrazolopyrimidines
  申请人：Bacon R. Edward

  公开号：US20070281949A1

  公开（公告）日：2007-12-06

  The present invention is related to chemical compositions, processes for the preparation thereof and uses of the composition. Particularly, the present invention relates to compositions that include substituted heterobicyclic pyrimidines of Formula (I): wherein R 1 , R 2 , R 3 , R 4 , R 5 , X, W, and ring A are as defined herein; pharmaceutical compositions of substituted heterobicyclic pyrimidines of Formula (I); and their use in the treatment of chronic neurodegenerative diseases, neurotraumatic diseases, depression and/or diabetes. More particularly, the present invention relates to substituted pyrazolopyrimidines of Formula (I).

  本发明涉及化学组合物、其制备方法以及组合物的用途。特别是，本发明涉及包括式（I）的取代杂环嘧啶的组合物：其中R1、R2、R3、R4、R5、X、W和环A如本文所定义；取代杂环嘧啶的药物组合物；以及它们在治疗慢性神经退行性疾病、神经创伤性疾病、抑郁症和/或糖尿病中的用途。更具体地，本发明涉及式（I）的取代吡唑嘧啶。